142 related articles for article (PubMed ID: 37170558)
1. Surgical indication of type I gastric neuroendocrine tumors.
Ruiz Pardo J; Sánchez Fuentes PA; Vidaña Márquez E; García-Redondo M; González Sánchez D; Belda Lozano R; Ferrer-Márquez M; Reina Duarte Á
Rev Esp Enferm Dig; 2024 May; 116(5):280-282. PubMed ID: 37170558
[TBL] [Abstract][Full Text] [Related]
2. A 15-year experience with gastric neuroendocrine tumors: Does type make a difference?
Postlewait LM; Baptiste GG; Ethun CG; Le N; Cardona K; Russell MC; Willingham FF; Kooby DA; Staley CA; Maithel SK
J Surg Oncol; 2016 Oct; 114(5):576-580. PubMed ID: 27393718
[TBL] [Abstract][Full Text] [Related]
3. The Morphologic Spectrum of Gastric Type 1 Enterochromaffin-Like Cell Neuroendocrine Tumors.
Poveda JC; Chahar S; Garcia-Buitrago MT; Montgomery EA; McDonald OG
Mod Pathol; 2023 Apr; 36(4):100098. PubMed ID: 36913909
[TBL] [Abstract][Full Text] [Related]
4. [Gastric neuroendocrine tumors].
Alekberzade AV; Krylov NN; Lipnitskiy EM; Shakhbazov RO; Azari F
Khirurgiia (Mosk); 2019; (12):111-120. PubMed ID: 31825351
[TBL] [Abstract][Full Text] [Related]
5. [Gastric neuroendocrine tumors: clinical, endoscopic presentation and alternatives of treatment].
Lazarte R; Poniachik J; Smok G; Contreras J; Gutiérrez L; Csendes A
Rev Med Chil; 2002 Sep; 130(9):985-92. PubMed ID: 12434645
[TBL] [Abstract][Full Text] [Related]
6. Classification, clinicopathologic features and treatment of gastric neuroendocrine tumors.
Li TT; Qiu F; Qian ZR; Wan J; Qi XK; Wu BY
World J Gastroenterol; 2014 Jan; 20(1):118-25. PubMed ID: 24415864
[TBL] [Abstract][Full Text] [Related]
7. Enterochromaffin-like Cell Hyperplasia-Associated Gastric Neuroendocrine Tumors May Arise in the Setting of Proton Pump Inhibitor Use.
Rais R; Trikalinos NA; Liu J; Chatterjee D
Arch Pathol Lab Med; 2022 Mar; 146(3):366-371. PubMed ID: 34283890
[TBL] [Abstract][Full Text] [Related]
8. Clinical features and outcomes of gastric neuroendocrine tumors after endoscopic diagnosis and treatment: A Digestive Endoscopy Society of Tawian (DEST).
Chung CS; Tsai CL; Chu YY; Chen KC; Lin JC; Chen BC; Sun WC; Yen HH; Chen CY; Wu IC; Kuo CH; Shih HY; Bair MJ; Wang JP; Hu WH; Yang CS; Han ML; Cheng TY; Tseng CM; Tsai MC; Hu ML; Wang HP
Medicine (Baltimore); 2018 Sep; 97(38):e12101. PubMed ID: 30235663
[TBL] [Abstract][Full Text] [Related]
9. Gastric neuroendocrine neoplasms.
Lamberti G; Panzuto F; Pavel M; O'Toole D; Ambrosini V; Falconi M; Garcia-Carbonero R; Riechelmann RP; Rindi G; Campana D
Nat Rev Dis Primers; 2024 Apr; 10(1):25. PubMed ID: 38605021
[TBL] [Abstract][Full Text] [Related]
10. Netazepide Inhibits Expression of Pappalysin 2 in Type 1 Gastric Neuroendocrine Tumors.
Lloyd KA; Parsons BN; Burkitt MD; Moore AR; Papoutsopoulou S; Boyce M; Duckworth CA; Exarchou K; Howes N; Rainbow L; Fang Y; Oxvig C; Dodd S; Varro A; Hall N; Pritchard DM
Cell Mol Gastroenterol Hepatol; 2020; 10(1):113-132. PubMed ID: 32004755
[TBL] [Abstract][Full Text] [Related]
11. Recurrent gastric neuroendocrine tumors treated with total gastrectomy.
Jung M; Kim JW; Jang JY; Chang YW; Park SH; Kim YH; Kim YW
World J Gastroenterol; 2015 Dec; 21(46):13195-200. PubMed ID: 26675502
[TBL] [Abstract][Full Text] [Related]
12. The role of 68-Ga-DOTATOC CT-PET in surgical tactic for gastric neuroendocrine tumors treatment: our experience: a case report.
Cavallaro A; Zanghì A; Cavallaro M; Lo Menzo E; Di Carlo I; Di Vita M; Cardì F; Piccolo G; Di Mattia P; Cappellani A
Int J Surg; 2014; 12 Suppl 1():S225-31. PubMed ID: 24862665
[TBL] [Abstract][Full Text] [Related]
13. [Autoimmune metaplastic atrophic gastritis, G cell hyperplasia and neuroendocrine tumor of stomach].
Chen G; Huang S
Zhonghua Bing Li Xue Za Zhi; 2014 Jan; 43(1):34-5. PubMed ID: 24713247
[No Abstract] [Full Text] [Related]
14. Gastric Neuroendocrine Tumors: Reappraisal of Type in Predicting Outcome.
Hanna A; Kim-Kiselak C; Tang R; Metz DC; Yang Z; DeMatteo R; Fraker DL; Roses RE
Ann Surg Oncol; 2021 Dec; 28(13):8838-8846. PubMed ID: 34120268
[TBL] [Abstract][Full Text] [Related]
15. Endoscopic diagnosis and management of type I neuroendocrine tumors.
Sato Y
World J Gastrointest Endosc; 2015 Apr; 7(4):346-53. PubMed ID: 25901213
[TBL] [Abstract][Full Text] [Related]
16. CEA Level, Radical Surgery, CD56 and CgA Expression Are Prognostic Factors for Patients With Locoregional Gastrin-Independent GNET.
Li Y; Bi X; Zhao J; Huang Z; Zhou J; Li Z; Zhang Y; Li M; Chen X; Hu X; Chi Y; Zhao D; Zhao H; Cai J
Medicine (Baltimore); 2016 May; 95(18):e3567. PubMed ID: 27149478
[TBL] [Abstract][Full Text] [Related]
17. Defining prognostic parameters of well-differentiated gastric neuroendocrine tumors based on metastatic potential: a two-center experience.
Kurtulan O; Turhan N; Gedikoğlu G; Akyol A; Sökmensüer C
Acta Gastroenterol Belg; 2022; 85(2):339-345. PubMed ID: 35709778
[TBL] [Abstract][Full Text] [Related]
18. Histidine decarboxylase and urinary methylimidazoleacetic acid in gastric neuroendocrine cells and tumours.
Tsolakis AV; Grimelius L; Granerus G; Stridsberg M; Falkmer SE; Janson ET
World J Gastroenterol; 2015 Dec; 21(47):13240-9. PubMed ID: 26715806
[TBL] [Abstract][Full Text] [Related]
19. Long-term results of endoscopic resection for type I gastric neuroendocrine tumors.
Uygun A; Kadayifci A; Polat Z; Yilmaz K; Gunal A; Demir H; Bagci S
J Surg Oncol; 2014 Feb; 109(2):71-4. PubMed ID: 24165913
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of endoscopic submucosal dissection for gastrointestinal neuroendocrine tumors: a 10-year data analysis of Northern China.
Chen X; Li B; Wang S; Yang B; Zhu L; Ma S; Wu J; He Q; Zhao J; Zheng Z; Li S; Wang T; Liang L
Scand J Gastroenterol; 2019 Mar; 54(3):384-389. PubMed ID: 31037980
[No Abstract] [Full Text] [Related]
[Next] [New Search]
